[Anti-beta 2 glycoprotein I antibodies in systemic lupus erythematosus: a marker of thrombosis associated with a circulating anticoagulant].
An ELISA technique for the detection of anti-beta 2 glycoprotein I (beta 2gp I) antibodies was developed. Among 47 systemic lupus erythematosus patients, 17 had anti-beta 2gp I antibodies. These antibodies were statistically associated with anticardiolipin antibodies, lupus anticoagulant and thrombosis. Out of 18 patients with anticardiolipin antibodies without anti-beta 2gp I antibodies or lupus anticoagulant, only one had thrombosis (due to nephrotic syndrome). Therefore the presence of anti-beta 2gp I antibodies is a new immunologic marker of lupus patients with thrombosis. In addition, we propose that anti-beta 2gp I antibodies may be directly responsible for lupus anticoagulant activity.
Viard
J P
JP
Sercice d'Immunologie clinique-I.N.S.E.R.M. U25, Hôpital Necker, Paris.
Amoura
Z
Z
Bach
J F
JF
D000906:Antibodies / Q000032:analysis*; D001777:Blood Coagulation / Q000276:immunology*; D002308:Cardiolipins / Q000276:immunology*; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000097:blood / Q000150:complications / Q000453:epidemiology / Q000276:immunology*; D012189:Retrospective Studies; D013927:Thrombosis / Q000209:etiology; D053482:beta 2-Glycoprotein I
D000906:Antibodies; D002308:Cardiolipins; D006023:Glycoproteins; D053482:beta 2-Glycoprotein I
Anticorps anti-beta 2 glycoprotéine I dans le lupus érythémateux disséminé: un marqueur des thromboses associées à l'anticoagulant circulant.